

Supplementary table 1. Joint effects between allergic diseases in association with myopia in the case-control study population.

AS	AD	AR	AC	Non-myopia group	Myopia group	Adjusted OR (95% CI)
-	-	-	-	93056	70708	Ref.
+	-	-	-	9538	7722	1.07 (1.03-1.10)
-	+	-	-	3523	3164	1.18 (1.13-1.24)
-	-	+	-	25375	26601	1.40 (1.37-1.42)
-	-	-	+	17251	23484	1.82 (1.78-1.86)
+	+	-	-	626	603	1.27 (1.13-1.42)
+	-	+	-	17108	17153	1.34 (1.31-1.37)
+	-	-	+	2160	2989	1.85 (1.75-1.96)
-	+	+	-	2298	2391	1.39 (1.31-1.47)
-	+	-	+	986	1533	2.08 (1.92-2.26)
-	-	+	+	10364	17692	2.30 (2.24-2.36)
+	+	+	-	3253	3209	1.32 (1.25-1.39)
+	+	-	+	193	326	2.25 (1.89-2.69)
+	-	+	+	7878	13360	2.29 (2.22-2.36)
-	+	+	+	1398	2500	2.41 (2.25-2.57)
+	+	+	+	2230	3802	2.31 (2.19-2.44)

Abbreviation: AS, asthma; AD, atopic dermatitis; AR, allergic rhinitis; AC, allergic conjunctivitis; OR, odds ratio; CI, confidence interval

Adjusted for sex, age, urbanization, and parents' occupational status

All $p < 0.001$


Supplementary Figure legend

Supplementary Figure 1: Allergic conjunctivitis increased the expression of myopia-related tissue-remodeling proteins. Immunofluorescence staining of TGF- β , MMP2, and COL-I in negative, PBS-treated, and OVA-treated eyes are shown.

Supplementary Figure 2: TNF- α , IL-6, IL-8, and MCP-1 increased, while IL-10 down-regulated in allergic conjunctivitis eyes. Immunofluorescence staining of TNF- α , IL-6, IL-8, MCP-1, and IL-10 expressions in negative, PBS-treated, and OVA-treated eyes.


Supplementary Figure 3: NF κ B and I κ B increased in allergic conjunctivitis eyes. Immunofluorescence staining of NF κ B and I κ B expressions in negative, PBS-treated, and OVA-treated eyes.

Supplemental
Figure 1



* Scale bar indicate 40 μ M

Supplemental
Figure 2



* Scale bar indicate 40 μ M

Supplementary
Figure 3

